iCAD, Inc. (ICAD)
| Chiusura precedente | 3,2300 |
| Aperto | 3,2500 |
| Denaro | 3,4100 x 900 |
| Lettera | 3,4800 x 800 |
| Min-Max giorno | 3,1100 - 3,5200 |
| Intervallo di 52 settimane | 2,9100 - 12,7300 |
| Volume | |
| Media Volume | 155.466 |
| Capitalizzazione | 85,387M |
| Beta (5 anni mensile) | 1,08 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5240 |
| Prossima data utili | 07 nov 2022 - 11 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,67 |
- GlobeNewswire
iCAD Reports Financial Results For Second Quarter 2022
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., Aug. 10, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for
- GlobeNewswire
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022. August 10, 2022 at 4:30 PM ETDomestic: 888-506-0062 International: 973-528-0011 Conference ID: 718241 Webcast: https://www.webcaster4.c
- GlobeNewswire
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general populationNASHUA, N.H., July 13, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company will showcase and demonstrate the complete portfolio of its Breast AI solutions, including ProFound AI®, PowerLook® Density A
